Treatment of choroidal neovascularization in high myopia

Current Drug Targets

Volumn 11, Issue 5, 2010, Pages 630-644

  Montero, Javier A ^a,b   Ruiz Moreno, Jose M ^b,c  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Retina Unit ^*  (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Bevacizumab; Choroidal neovascularization; High myopia; Pegaptanib; Photodynamic therapy; Ranibizumab; Triamcinolone

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

CONJUNCTIVITIS; DRUG COST; DRUG TARGETING; ENDOPHTHALMITIS; HEART DISEASE; HEART RATE; HIGH MYOPIA; HUMAN; HYPERTENSION; ISCHEMIA; KERATITIS; LASER COAGULATION; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA SURGERY; RETINA TEAR; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TRAUMATIC CATARACT; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; HUMANS; INJECTIONS, INTRAOCULAR; MYOPIA, DEGENERATIVE; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 77951068897     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791011929     Document Type: Review

References (178)

1. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol 2004; 15: 197-202. (Pubitemid 38638864)
2. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008; 53: 121-138 (Pubitemid 351381556)
3. Novack GD. Pharmacotherapy for the Treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008; 48: 61-78. (Pubitemid 351738149)
4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103: 1241-1244 (Pubitemid 26282507)
5. Tokoro T. On the definition of pathologic myopia in group studies. Acta Ophthalmol 1988; 185(Suppl): 107-108
6. Riise R. Myopia as a cause of blindness. Acta Ophthalmol 1988; 185(Suppl): 109-110
7. Pruett RC. Pathologic Myopia. In: Albert DM, Jakobiec FA, Eds. Principles and practice of ophthalmology. Philadelphia: WB Saunders Company 1994; pp. 878-889.
8. Metge P. Definitions. In: Mondon H, Metge P, Eds. La myopie forte. Paris: Masson 1994; pp. 14-17.
9. Legeais JM, Parel JM, Savoldelli M, et al. Reticulated polyethylene oxide for gel injection adjustable keratoplasty. Biocompatibility in critical situation. J Fr Ophtalmol 1997; 20: 31-36 (Pubitemid 27077334)
10. 1Ruben M, Rajpurohit P. Distribution of myopia in aphakic retinal detachments. Br J Ophthalmol 1976; 60: 517-521
11. Curtin BJ, Ed. The Myopias: basic science and clinical management. Philadelphia: Harper & Row 1985.
12. Ducourneau D, Korobelnik JF, Le Mer Y, Mondon M, Quentel G. Neovascularization in severe myopia. J Fr Ophtalmol 1998; 21: 782-784
13. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992; 12: 127-133
14. Incidence of myopia among Talmudical Ieshiva students. Third International Conference on Myopia; Roma 1986.
15. Jacobsen N, Jensen H, Goldschmidt E. Does the level of physical activity in university students influence development and progression of myopia? - a 2-year prospective cohort study. Invest Ophthalmol Vis Sci 2008; 49: 1322-1327
16. Rosner M, Belkin M. Intelligence, education and myopia in males. Arch Ophthalmol 1987; 105: 1508-1511
17. Miller DG, Singerman LJ. Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 2001; 12: 222-224
18. Vongphanit R, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002; 109: 704-711 (Pubitemid 34270127)
19. Van Alphen GWHM. Choroidal stress and emmetropization. Vision Res 1986; 26: 723-734
20. Yinon U. Myopia induction in animals following alteration of the visual input during development: a review. Curr Eye Res 1984; 3: 677-690 (Pubitemid 14173074)
21. Ambani LM, Gelehrter TD, Sheahan DG. Variable expression of Marfan syndrome in monozygotic twins. Clin Genet 1975; 8: 358-363
22. Valkova M. Atypical forms of Marfan's syndrome. Cesk Opthalmol 1971; 27: 65-72.
23. Heilmann K, Suschke J, Murken JD. Marfans syndrome. Ber Zusammenkunft Dtsch Ophthalmol Ges 1970; 70: 599-601.
24. Spallone A. Stickler's syndrome: a study of 12 families. Br J Ophthalmol 1987; 71: 504-509
25. Herrmann J, France TD, Opitz JM. The Stickler syndrome. Birth Defects Orig Artic Ser 1975; 11: 203-204
26. Hall J. Stickler syndrome. Presenting as a syndrome of cleft palate, myopia and blindness inherited as a dominant trait. Birth Defects Orig Artic Ser 1974; 10: 157-171
27. Marr JE, Halliwell-Ewen J, Fisher B, Soler L, Ainsworth JR. Associations of high myopia in childhood. Eye 2001; 15: 70-74
28. Forster W, Lenz W, Busse H. Ocular symptoms in a family with pseudo-Ullrich-Turner syndrome. Klin Monatsbl Augenheilkd 1991; 199: 362-366
29. Schwartz DE. Noonan's syndrome associated with ocular abnormalities. Am J Ophthalmol 1972; 73: 955-960
30. Francois J. Autosomal chromosome aberrations in ophthalmology. Int Ophthalmol Clin 1968; 8: 839-910.
31. Wertelecki W, Smith LT, Byers P. Initial observations of human dermatosparaxis: Ehlers-Danlos syndrome type VIIC. J Pediatr 1992; 121: 558-564
32. Beighton P. Serious ophthalmological complications in the Ehlers-Danlos syndrome. Br J Ophthalmol 1970; 54: 263-268
33. Pemberton JW, Freeman HM, Schepens CL. Familial retinal detachment and the Ehlers-Danlos syndrome. Arch Ophthalmol 1966; 76: 817-824
34. Nishizaki R, Ota M, Inoko H, et al. New susceptibility locus for high myopia is linked to the uromodulin-like 1 (UMODL1) gene region on chromosome 21q22.3. Eye 2009; 23: 222-229
35. Bourla DH, Young TA. Age-related macular degeneration: a practical approach to a challenging disease. J Am Geriatr Soc 2006; 54: 1130-1135 (Pubitemid 43992553)
36. Hattenbach LO, Falk B, Nurnberger F, Koch FH, Ohrloff C. Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica 2002; 216: 209-214 (Pubitemid 34639073)
37. Naiglin L, Gazagne C, Dallongeville F, et al. A genome wide scan for familial high myopia suggests a novel locus on chromosome 7q36. J Med Genet 2002; 39: 118-124 (Pubitemid 34146381)
38. Paluru P, Ronan SM, Heon E, et al. New locus for autosomal dominant high myopia maps to the long arm of chromosome 17. Invest Ophthalmol Vis Sci 2003; 44: 1830-1836 (Pubitemid 36520269)
39. Zhou J, Pham L, Zhang N, et al. Neutrophils promote experimental choroidal neovascularization. Mol Vis 2005; 11: 414-424 (Pubitemid 41410238)
40. Schache M, Chen CY, Pertile KK, et al. Fine mapping linkage analysis identifies a novel susceptibility locus for myopia on chromosome 2q37 adjacent to but not overlapping MYP12. Mol Vis 2009; 15: 722-730
41. Paluru PC, Nallasamy S, Devoto M, Rappaport EF, Young TL. Identification of a novel locus on 2q for autosomal dominant highgrade myopia. Invest Ophthalmol Vis Sci 2005; 46: 2300-2307 (Pubitemid 43119472)
42. Schwartz M, Haim M, Skarsholm D. X-linked myopia: Bornholm eye disease. Linkage to DNA markers on the distal part of Xq. Clin Genet 1990; 38: 281-286
43. Yu ZQ, Li YB, Huang CX, et al. A genome-wide screening for pathological myopia suggests a novel locus on chromosome 15q12 - 13. Zhonghua Yan Ke Za Zhi 2007; 43: 233-238
44. Nallasamy S, Paluru PC, Devoto M, Wasserman NF, Zhou J, Young TL. Genetic linkage study of high-grade myopia in a Hutterite population from South Dakota. Mol Vis 2007; 13: 229-236 (Pubitemid 46306513)
45. Li YJ, Guggenheim JA, Bulusu A, et al. An international collaborative family-based whole-genome linkage scan for high-grade myopia. Invest Ophthalmol Vis Sci 2009; 50: 3116-3127
46. Ciner E, Wojciechowski R, Ibay G, Bailey-Wilson JE, Stambolian D. Genomewide scan of ocular refraction in African-American families shows significant linkage to chromosome 7p15. Genet Epidemiol 2008; 32: 454-463
47. Lam CY, Tam PO, Fan DS, et al. A genome-wide scan maps a novel high myopia locus to 5p15. Invest Ophthalmol Vis Sci 2008; 49: 3768-3778
48. Paget S, Vitezica ZG, Malecaze F, Calvas P. Heritability of refractive value and ocular biometrics. Exp Eye Res 2008; 86: 290-295
49. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26: 204-210
50. Ciner E, Ibay G, Wojciechowski R, et al. Genome-wide scan of African-American and white families for linkage to myopia. Am J Ophthalmol 2009; 147: 512-e2.
51. Zhang Q, Guo X, Xiao X, Yi J, Jia X, Hejtmancik JF. Clinical description and genome wide linkage study of Y-sutural cataract and myopia in a Chinese family. Mol Vis 2004; 10: 890-900. (Pubitemid 41358203)
52. Lopes MC, Andrew T, Carbonaro F, Spector TD, Hammond CJ. Estimating heritability and shared environmental effects for refractive error in twin and family studies. Invest Ophthalmol Vis Sci 2009; 50: 126-131
53. Weng LM, Wang X, Wang L, Jin F. Myopia and genetics. Yi Chuan 2006; 28: 486-492
54. Phillips JR, McBrien NA. Form deprivation myopia: elastic properties of sclera. Ophthalmic Physiol Opt 1995; 15: 357-362
55. McBrien NA, Jobling AI, Gentle A. Biomechanics of the sclera in myopia: extracellular and cellular factors. Optom Vis Sci 2009; 86: E23-30.
56. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1048-1053
57. Pruett RC. Progressive myopia and intraocular pressure: what is the linkage? A literature review. Acta Ophthalmol Suppl 1988; 185: 117-127
58. Pruett RC. Progressive myopia and intraocular pressure: what is the linkage? Acta Ophthalmol 1988; 66(suppl 185): 117-127
59. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology 2009; 116: 572-579
60. Fan DS, Lam DS, Chan CK, Fan AH, Cheung EY, Rao SK. Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study. Jpn J Ophthalmol 2007; 51: 27-33.
61. Syniuta LA, Isenberg SJ. Atropine and bifocals can slow the progression of myopia in children. Binocul Vis Strabismus Q 2001; 16: 203-208
62. Levy JH, Pollock HM, Curtin BJ. The Fuch's spot: An ophthalmoscopic and fluorescein angiographic study. Ann Ophthalmol 1977; 9: 1433-1443
63. Stafford TJ, Anness SH, Fine BS. Spontaneous degenerative maculopathy in the monkey. Ophthalmology 1984; 91: 513-521
64. Norton TT. Animal models of myopia: learning how vision controls the size of the eye. Ilar J 1999; 40: 59-77.
65. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 955-958
66. McBrien NA, Cornell LM, Gentle A. Structural and ultrastructural changes to the sclera in a mammalian model of high myopia. Invest Ophthalmol Vis Sci 2001; 42: 2179-2187 (Pubitemid 32848844)
67. Gentle A, Liu Y, Martin JE, Conti GL, McBrien NA. Collagen gene expression and the altered accumulation of scleral collagen during the development of high myopia. J Biol Chem 2003; 278: 16587-16594 (Pubitemid 36799520)
68. Metlapally R, Li YJ, Tran-Viet KN, et al. COL1A1, COL2A1 genes and myopia susceptibility: evidence of association and suggestive linkage to the COL2A1 locus. Invest Ophthalmol Vis Sci 2009; in press.
69. Hall NF, Gale CR, Ye S, Martyn CN. Myopia and polymorphisms in genes for matrix metalloproteinases. Invest Ophthalmol Vis Sci 2009; 50: 2632-2636
70. Frost MR, Norton TT. Differential protein expression in tree shrew sclera during development of lens-induced myopia and recovery. Mol Vis 2007; 13: 1580-1588 (Pubitemid 47385505)
71. Halfter W, Winzen U, Bishop PN, Eller A. Regulation of eye size by the retinal basement membrane and vitreous body. Invest Ophthalmol Vis Sci 2006; 47: 3586-3594 (Pubitemid 351639728)
72. Jobling AI, Nguyen M, Gentle A, McBrien NA. Isoform-specific changes in scleral transforming growth factor-beta expression and the regulation of collagen synthesis during myopia progression. J Biol Chem 2004; 279: 18121-18126 (Pubitemid 38623224)
73. Wallman J, Gottlieb MD, Rajaram V, A. Fugate-Wentzek LA. Local retinal regions control local eye growth and myopia. Science 1987; 237: 72-77 (Pubitemid 17096939)
74. Zadnik K, Mutti DO. How applicable are animal myopia models to human juvenile onset myopia? Vision Res 1995; 35: 1283-1288
75. Ohno-Matsui K, Ito M, Tokoro T. Subretinal bleeding without choroidal neovascularization in pathologic myopia. A sign of new lacquer crack formation. Retina 1996; 16: 196-202.
76. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141: 456-462 (Pubitemid 43265948)
77. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110: 1297-1305 (Pubitemid 36842462)
78. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-1581
79. Hotchkiss ML, Fine SL. Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981; 91: 177-183
80. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-926 (Pubitemid 13004305)
81. Brancato R, Pece A, Avanza P, Camesasca F. Laser treatment of subretinal macular neovascularization in pathologic myopia. J Fr Ophtalmol 1989; 12: 883-886 (Pubitemid 20241501)
82. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106: 2063-2067 (Pubitemid 30194225)
83. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 307-316 (Pubitemid 28042043)
84. Georgalas I, Ezra E. Delayed closure after surgery for a full-thickness macular hole in a highly myopic eye. Can J Ophthalmol 2007; 42: 341-342 (Pubitemid 46713709)
85. Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002; 12: 117-122
86. Shimada N, Ohno-Matsui K, Baba T, Futagami S, Tokoro T, Mochizuki M. Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment. Am J Ophthalmol 2006; 142: 497-500. (Pubitemid 44691736)
87. Shimada N, Ohno-Matsui K, Yoshida T, Futagami S, Tokoro T, Mochizuki M. Development of macular hole and macular retinoschisis in eyes with myopic choroidal neovascularization. Am J Ophthalmol 2008; 145: 155-161. (Pubitemid 350265753)
88. Morillo-Sánchez MJ, Rivera de Cea P, Vázquez-Salvi A, et al. Estudio de membranas neovasculares subretinianas secundarias a miopía degenerativa. Arch Soc Esp Oftalmol 2001; 76: 357-362
89. Rabb MF, Garoon I, LaFranco FP. Myopic macular degeneration. Int Ophthalmol Clin 1981; 21: 51-69.
90. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009; 23: 1275-80; quiz 1281.
91. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92: 792-794 (Pubitemid 351839570)
92. Bottoni F, Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001; 24: 249-255 (Pubitemid 37168157)
93. Curtin BJ. The posterior staphyloma of pathologic myopia. Trans Am Ophthalmol Soc 1977; 75: 67-86.
94. Gass JDM. Stereoscopic atlas of macular diseases: Diagnosis and treatment. St Louis: Mosby, 1999.
95. nd ed. St Louis: Mosby- Year Book, Inc. 1994.
96. Brancato R, Trabucchi G, Introini U, Avanza P, Pece A. Indocyanine green angiography (ICGA) in pathological myopia. Eur J Ophthalmol 1996; 6: 39-43. (Pubitemid 26143190)
97. Matsuda S, Harino S, Iwahashi Y, Nagaya C. Long-term enlargement of laser photocoagulation scars after treatment of choroidal neovascularization. Nippon Ganka Gakkai Zasshi 2002; 106: 708-713
98. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001; 85: 1041-1043
99. Horle S, Postgens H, Schmidt J, Kroll P. Pigment epithelium defects after submacular surgery for choroidal neovascularization: first results. Ophthalmologica 2000; 214: 122-125 (Pubitemid 30179207)
100. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000; 118: 344-350 (Pubitemid 30152374)
101. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003; 87: 173-176 (Pubitemid 36152743)
102. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 1117-1123
103. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114: 2190-2196
104. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007; 245: 903-905 (Pubitemid 46805624)
105. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006; 142: 335-337 (Pubitemid 44107278)
106. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000; 118: 327-336 (Pubitemid 30152372)
107. Verteporfin in Photodynamic Theory Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001; 108: 841-852
108. Yoshida T, Ohno-Matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002; 109: 712-719 (Pubitemid 34270128)
109. Pece A, Vadala M, Isola V, Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007; 143: 449-454 (Pubitemid 46298547)
110. Curcio CA, Saunders PL, Younger PW, Malek G. Peripapillary chorioretinal atrophy: Bruch's membrane changes and photoreceptor loss. Ophthalmology 2000; 107: 334-343 (Pubitemid 30191415)
111. Ruiz-Moreno JM, Amat P, Montero JA, Lugo FL. Photodynamic therapy to treat choroidal neovascularization in highly myopic patients: 4 years outcome. Br J Ophthalmol 2008; 92: 792-794 (Pubitemid 351839570)
112. Ladas ID, Moschos MM, Rouvas AA, Karagiannis DA, Kokolakis SN. Lacquer crack formation after photodynamic therapy. Eur J Ophthalmol 2003; 13: 729-733 (Pubitemid 37409135)
113. Diaz-de-Durana-Santa-Coloma E, Fernandez-Ares ML, Iturralde-Errea D, Salazar-Diez JL, Vazquez-Cruchaga E, Lopez-Garrido JA. Submacular heamorrhage following photodynamic therapy in the treatment of choroidal neovascularization. Arch Soc Esp Opthalmol 2006; 81: 685-691
114. Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 2003; 87: 856-859 (Pubitemid 36765249)
115. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007; 24: 643-662
116. Potter MJ, Szabo SM. Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 2007; 91: 753-756 (Pubitemid 46846645)
117. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002; 134: 566-576 (Pubitemid 35304647)
118. Moschos MN, Panayotidis D, Moschos MM, Bouros C, Theodossiadis PG, Theodossiadis GP. A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol 2003; 13: 461-467 (Pubitemid 36807131)
119. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 174-179 (Pubitemid 46202864)
120. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525 (Pubitemid 36962483)
121. Hunter MA, Dunbar MT, Rosenfeld PJ. Retinal angiomatous proliferation: clinical characteristics and treatment options. Optometry 2004; 75: 577-588
122. Hogan A, Behan U, Kilmartin DJ. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 2005; 89: 1109-1111 (Pubitemid 41224455)
123. Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004; 138: 884-885
124. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-347 (Pubitemid 38333711)
125. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304 (Pubitemid 40202568)
126. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006; 113: 2243-2250 (Pubitemid 44838921)
127. Augustin AJ, Offermann I. Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs 2006; 11: 725-740 (Pubitemid 44735595)
128. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006; 90: 337-341 (Pubitemid 43325467)
129. Ruiz-Moreno JM, Montero JA, de la Vega C, Alio JL, Zapater P. Macular choroidal neovascularization in myopic eyes after phakic intraocular lens implantation. J Refract Surg 2006; 22: 689-694 (Pubitemid 44379999)
130. Ergun E, Maar N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006; 142: 10-16. (Pubitemid 43946797)
131. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005; 25: 685-690 (Pubitemid 41254536)
132. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2005; 14: 671-682 (Pubitemid 40790287)
133. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-1282 (Pubitemid 37128405)
134. Anijeet DR, Hanson RJ, Bhagey J, Bates RA. National survey of the technique of intravitreal triamcinolone injection in the United Kingdom. Eye 2006.
135. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508 e1-25.
136. Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 2005; 83: 621. (Pubitemid 41488642)
137. Potter MJ, Szabo SM, Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch Clin Exp Ophthalmol 2006; 244: 639-641 (Pubitemid 43756934)
138. Montero JA, Ruiz-Moreno JM. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 131-133 (Pubitemid 46202852)
139. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444 (Pubitemid 44511558)
140. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816 (Pubitemid 40051904)
141. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511. (Pubitemid 44620390)
142. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431 (Pubitemid 44511557)
143. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390 (Pubitemid 44197628)
144. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008; 1308-1313
145. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756
146. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 311-318
147. Figurska M, Stankiewicz A. Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization - cases report. Klin Oczna 2008; 110: 387-391
148. Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007; 17: 620-626 (Pubitemid 47605773)
149. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 707-712 (Pubitemid 47051766)
150. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165 (Pubitemid 46202863)
151. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 157-160 (Pubitemid 46202862)
152. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009; 23: 2042-2045
153. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147: 84-93e1.
154. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147: 94-100 e1.
155. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009; 127: 13-21.
156. Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye 2009; [Epub ahead of print].
157. Yodoi Y, Tsujikawa A, Nakanishi H, et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009; 147: 816-824, 824 e1.
158. Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 609-618
159. Rheaume MA, Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008; 43: 576-580
160. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008; 28: 1308-1313
161. Hoeh AE, Schaal KB, Ach T, Dithmar S. Treatment of peripapillary choroidal neovascularization with intravitreal bevacizumab. Eur J Ophthalmol 2009; 19: 163-165
162. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008; 92: 1035-1039
163. Kojima A, Ohno-Matsui K, Futagami S, Shimada N, Tokoro T, Mochizuki M. Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization. Acta Ophthalmol Scand 2006; 84: 749-754 (Pubitemid 44688323)
164. Neroev VV, Riabina MV, Chikovani KR, Neroeva NV. Photodynamic therapy with visudine in combination with intravitreal kenalog in the treatment of choroidal neovascularization. Vestn Opthalmol 2009; 125: 55-57
165. Georgijevic A, Tomic Z. Photodynamic therapy of subfoveal choroidal neovascularization. Srp Arh Celok Lek 2007; 135(11-12): 629-634
166. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001e6.
167. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008.
168. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047 (Pubitemid 40797459)
169. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9. (Pubitemid 43946791)
170. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009; 93: 448-451
171. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 960-963 (Pubitemid 44547453)
172. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-1370 (Pubitemid 41638883)
173. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006; 26: 1093-1094 (Pubitemid 44973239)
174. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 2009; 23: 334-338
175. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009; 23: 1714-1718
176. Ziemssen F, Gelisken F. Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?. Klin Monatsbl Augenheilkd 2009; 226: 31-37
177. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008; 37: 591-593
178. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. Br J Ophthalmol 2007. (Pubitemid 47344908)